Clinical trials: Early-stage Parkinson's Disease
Parkinson's Disease
A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder)
This study is a double-blind, randomized, placebo-controlled, 2-way crossover study to evaluate the safety of CVT-301 levodopa (l-dopa) when co- administered with the first daily dose of oral levodopa/carbidopa for early morning…
- Trial name
- NCT02807675
- Testing
- CVT-301, LIP
- Where
- 11 sites in United States
- Volunteers
- 36 people
- Sponsor
- Acorda Therapeutics
Parkinson's Disease
Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist (12 Month Extension)
To determine the long-term safety and efficacy of a dose range of safinamide of 50-200 mg/day, p.o., compared to placebo, as add-on therapy in patients with early idiopathic Parkinson's disease who are currently receiving a…
- Trial name
- NCT00642889
- Testing
- Safinamide
- Volunteers
- 227 people
- Sponsor
- Newron Pharmaceuticals SPA
Parkinson's Disease
Study to Assess Real Life Effectiveness of Foslevodopa/Foscarbidopa in Adult German Participants at Initial Stages of Advanced Parkinson's Disease (EARLY-FOS)
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person.
- Trial name
- NCT06916507
- Where
- 19 sites in Germany
- Volunteers
- 125 people
- Sponsor
- AbbVie
Parkinson's Disease, Healthy
Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkinson's Disease
The primary objective of the study is to evaluate the safety and tolerability of a range of single BIIB054 doses, administered as a single intravenous (IV) infusion, in healthy participants and participants with early Parkinson's…
- Trial name
- NCT02459886
- Testing
- BIIB054
- Where
- 9 sites in United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Biogen
Parkinson Disease (PD), Gut Microbiota
Developing Precision Microbiota-Based Cocktail Modification Therapy to Delay the Progression of Parkinson's Disease (PD) - Use Preclinical Human Trials to Confirm the Impact of the Optimal "Probiotic Y7, Tryptophan and Branched-chain Amino Acid" Cocktail Formula on Early Stage PD Patients
Preclinical human trials will be utilized to validate the research direction, followed by clinical trials to assess the impact of a cocktail formula product containing the optimal probiotic Y7 combined metabolites on motor…
- Conditions
- Parkinson Disease (PD), Gut Microbiota, Probiotic
- Trial name
- NCT07619560
- Testing
- Y7
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- Taipei Medical University
Parkinson Disease
Efficacy, Safety, Tolerability, and Biomarker Effects of GT-02287 in Early Parkinson's Disease
The purpose of this study is to assess the efficacy, the safety, and the effect on biomarkers of 2 dose levels of oral GT-02287 over placebo after 48 weeks of treatment in treated and untreated participants with early PD.
- Trial name
- NCT07280299
- Testing
- Low Dose GT-02287, High Dose GT-02287
- Volunteers
- 111 people
- Sponsor
- Gain Therapeutics, Inc.
Parkinson's Disease
Investigation of Cogane (PYM50028) in Early-stage Parkinson's Disease (CONFIDENT-PD)
A study to test the therapeutic benefit of the compound PYM50028, versus placebo, in treating early-stage Parkinson's disease. Therapeutic benefit will be assessed using the Unified Parkinson's Disease Rating Scale (UPDRS).
- Trial name
- CONFIDENT-PD (NCT01060878)
- Testing
- PYM50028
- Where
- 111 sites in United States, Canada and 8 more
- Volunteers
- 425 people
- Sponsor
- Phytopharm
Parkinson Disease
Parkinson's Disease (PD) Treated With Focused Ultrasound Subthalamotomy at an Early Stage
Parkinson's disease (PD) is a common, progressive, incurable neurodegenerative disease that can result in severe disability and impairment in health-related quality of life.
- Trial name
- EarlyFocus (NCT04692116)
- Testing
- ExAblate treatment
- Where
- Spain
- Volunteers
- 12 people
- Sponsor
- Fundación de investigación HM
Parkinson's Disease
Randomized Evaluation of the 24-Hour Coverage: Efficacy of Rotigotine
The objective of this trial is to assess the effects of transdermal rotigotine on the control of early morning motor function and sleep disorders compared to placebo in subjects with idiopathic Parkinsons´s disease.
- Trial name
- RECOVER (NCT00474058)
- Testing
- Rotigotine
- Where
- 47 sites in United States, Australia and 10 more
- Volunteers
- 287 people
- Sponsor
- UCB Pharma
Parkinson Disease
Identification of a Biomarker Predictive of Evolution of Parkinson Disease
Phase II, Open-labeled, Prospective, Multi-center study of assessing the link between microglial activation and dopaminergic denervation kinetics in the early stage of Parkinson disease, by using the imaging of [18F]DPA-714 a new…
- Trial name
- GLIAPARK (NCT03230526)
- Testing
- [18F]DPA-714 PET scan
- Where
- 4 sites in France
- Volunteers
- 31 people
- Sponsor
- Nantes University Hospital
Parkinson's Disease
A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease Patients
The purpose of this study is to evaluate the efficacy and safety of TVP-1012 (1 mg/day) administered to Japanese patients with early Parkinson's disease.
- Trial name
- NCT02337725
- Testing
- TVP-1012
- Where
- 55 sites in Japan
- Volunteers
- 244 people
- Sponsor
- Takeda
Parkinson's Disease
Efficacy and Safety of Rotigotine in the Treatment of Patients With Early Stage of Primary Parkinson's Disease
The efficacy and safety of rotigotine in the treatment of patients with early stage of primary Parkinson's disease
- Trial name
- NCT04455555
- Testing
- LY03003( the name of rotigotine)
- Where
- China
- Volunteers
- 294 people
- Sponsor
- Peking University Third Hospital
Early Onset Parkinson Disease, Early Stage Parkinson Disease
Dual-task Performance in Young-onset PD
This study aimed to investigate the effects of Game based dual-task training with treadmill on executive function and dual-task performance in individuals with early-onset PD and discuss the correlation between the change values…
- Trial name
- NCT04033393
- Testing
- Game based dual-task training, Treadmill training
- Volunteers
- 40 people
- Sponsor
- National Yang Ming Chiao Tung University
Early Parkinson Disease
PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706
This study consists of 2 parts. Part 1 of the study is conducted to evaluate the efficacy, safety, and tolerability of two doses of K0706 compared to placebo in subjects with early Parkinson's Disease who are not receiving…
- Trial name
- NCT03655236
- Testing
- K0706
- Where
- 78 sites in United States, Hungary and 4 more
- Volunteers
- 513 people
- Sponsor
- Sun Pharma Advanced Research Company Limited
Parkinson Disease, Neurodegenerative Diseases
Study Assessing Tolerability and Safety of AFFITOPE® PD03A in Patients With Early Parkinson's Disease
Study AFF011 is a randomized controlled parallel Group phase I study to investigate the safety and tolerability of two doses of the vaccine AFFITOPE® PD03A given to patients with early Parkinson's disease.
- Trial name
- AFF011 (NCT02267434)
- Testing
- Low dose AFFITOPE® PD03A + Adjuvant, High dose AFFITOPE® PD03A + Adjuvant, Adjuvant without active component
- Where
- 2 sites in Austria
- Volunteers
- 36 people
- Sponsor
- Affiris AG
Parkinson Disease
Study on the Safety, Tolerance and Pharmacokinetics of Phenlarmide Tablets
1. To evaluate the safety and tolerability of Phenlarmide tablets in patients with Parkinson's disease in the early and middle stages. 2.
- Trial name
- NCT04693039
- Testing
- Phenlarmide
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shijiazhuang Yiling Pharmaceutical Co. Ltd
Parkinson Disease
Study of the Neuro-protective Effect of Granulocyte-colony Stimulating Factor on Early Stage Parkinson's Disease
The purpose of this study is to evaluate the effectiveness of neuroprotection from granulocyte colony-stimulating factor on Parkinson disease
- Trial name
- NCT01227681
- Testing
- G-CSF
- Where
- Taiwan
- Volunteers
- 4 people
- Sponsor
- Buddhist Tzu Chi General Hospital
Early Stage Parkinson's Disease
The Effects of Aplindore on the Treatment of Signs and Symptoms of Parkinson's Disease
The purpose of this study is to demonstrate the safety, tolerability, efficacy and pharmacokinetics of aplindore in patients with early stage Parkinson's Disease (PD) who are not currently taking any dopamine agonists or who are…
- Trial name
- NCT00623324
- Testing
- Aplindore
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Ligand Pharmaceuticals
Parkinson's Disease
Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's Disease
The purpose of this study is to characterize the pharmacokinetics (PK) of LY03003 following multiple escalating intramuscular injections, as compared to Neupro patch and to evaluate the safety and tolerability and preliminary…
- Trial name
- 03003MAD (NCT02055274)
- Testing
- LY03003, Neupro
- Where
- 5 sites in United States
- Volunteers
- 39 people
- Sponsor
- Luye Pharma Group Ltd.
Parkinson's Disease
Dose-Finding Safety Study of BIIB014 in Early-Stage Parkinson's Disease
The main purpose of this study is to determine the safety of BIIB014 and how well BIIB014 is tolerated when given at different doses to patients with early-stage Parkinson's Disease.
- Trial name
- MOBILE (NCT00442780)
- Testing
- BIIB014
- Where
- 10 sites in Israel, Poland and 1 more
- Volunteers
- 36 people
- Sponsor
- Biogen